Citable ownership snapshot
CVS's latest 13F holder table lists Citadel Advisors as the largest holder in this view with 10,290,230 shares valued at $1.06B.
| Holder | Report date | Value | Portfolio weight |
|---|---|---|---|
| Citadel Advisors | Jun 30, 2026 | $1.06B | 0.1% |
| Glenview Capital Management | Jun 30, 2026 | $499.13M | 9.1% |
| Viking Global Investors | Jun 30, 2026 | $378.97M | 1.1% |
| AQR Capital Management | Jun 30, 2026 | $248.94M | 0.1% |
| Millennium Management | Jun 30, 2026 | $246.47M | 0.1% |
| D.E. Shaw & Co. | Jun 30, 2026 | $233.61M | 0.1% |
| Point72 Asset Management | Jun 30, 2026 | $211.31M | 0.2% |
| Sachem Head Capital Management | Dec 31, 2025 | $205.15M | 4.8% |
Source: SEC EDGAR 13F filings; period Jun 30, 2026; filed Sep 2, 2026.
CVS company research is free during early access. All you need is an account, with no card required. The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay open without one.
Continue research
Follow same-sector companies and source explainers connected to the ownership view.
A factual guide to 13F filings, what they show, what they omit, and how Aerarium Research turns them into holder and overlap views.
A factual guide to Schedule 13D and 13G beneficial ownership reports for holders with more than 5% stakes.
A factual guide to definitive proxy statements, shareholder voting matters, board information, and executive compensation disclosures.
A factual guide to Form 4 — who must file, what insider buys and sells disclose, and why a single transaction rarely explains itself.